New draft guidance from the US Food and Drug Administration would mandate that patients considering Laser-Assisted in Situ Keratomileusis (LASIK) get additional information about potential risks of the popular vision-correcting treatment.
The agency hopes that the 28 July guidance will help ensure that patients and health care providers can access clear...








